UNH HUM Investment Analysis, Two Giants on Sale — But Which One Do You Actually Want?

Watching a stock you know well drop by almost half in less than two years causes a certain kind of discomfort for investors. Over the past 18 months, UnitedHealth Group, which for a long time was the type of stock that institutional funds owned almost automatically, a position so dependable it hardly needed justification, has taken actions that have significantly reduced the weight of many portfolios. The decline from a 52-week high of $594.81 to a recent price of about $314 is the kind of thing that is discreetly brought up in quarterly reviews before being forgotten over dinner. With a 43% year-over-year decline in EPS, Humana has experienced a similar tale. Two businesses that once printed money for their owners are now in need of a new justification for their ownership.

The Centers for Medicare & Medicaid Services followed. CMS finalized a 2.48% increase in Medicare Advantage payment rates for 2027 on a Monday in early April. This figure may seem modest, but keep in mind that analysts had been anticipating a 0.09% increase, and the January proposal wasn’t much better. With both UNH and HUM rising more than 8% in a single session, the discrepancy between expectations and results was significant enough to cause a real relief rally. It is uncommon for mature, defensive healthcare names to make such a move. It reveals the extent to which the market had been pricing in a worst-case scenario and the speed at which sentiment can change when the government takes a different stance.

Company snapshot — UNH vs HUM

More than $13 billion in additional Medicare Advantage payments will flow to insurers in 2027 as a result of the CMS ruling. It’s not a rounding error. This type of rate clarity is very helpful for businesses whose profit margins have been squeezed by growing medical expenses, unexpectedly high patient utilization after the pandemic, and regulatory uncertainty. It provides actuaries with a tangible benchmark for modeling. It provides CFOs with a foundation for direction. Additionally, it provides an excuse for analysts to reevaluate EPS projections that had been steadily declining for several quarters.

As this develops, the more intriguing question is not whether UnitedHealth and Humana will recover, but rather which one does so more quickly and in what form. Despite their apparent similarities, these two businesses are in very different positions going into the next cycle, which makes the comparison instructive. The larger, slower-moving entity is UnitedHealth. It is anticipated that its revenue will slightly decline this year before rising to a projected $457 billion in FY27. In contrast, earnings per share are expected to increase to $19.95 by FY27, which is a significant increase but still less than the $20+ EPS the company was recording during its peak years from 2022 to 2024. UNH seems to be reestablishing itself rather than making significant progress.

In the short term, Humana’s story is more complicated. Most investors would recoil at the projected FY26 EPS of $9.70 compared to last year’s $17.14. Although the company’s top-line growth appears to be improving—revenue is predicted to increase by 24% this year—sophisticated investors are more likely to be alarmed than excited by revenue growth without supporting earnings. Humana’s EPS is expected to increase to $15.43 in FY27, which is a mitigating factor. In hindsight, the current price might seem cheap if that happens. It’s possible that UnitedHealth is the more stable and defendable position in this trade, while Humana is the higher-risk, higher-upside side.

Both names’ valuations are now much more intriguing. UnitedHealth is trading at about 15 to 16 times forward earnings, which is significantly less than the 22x multiple of the S&P 500 and roughly in line with the managed-care industry average. That multiple carries a certain logic as an entry point for a company of UNH’s size, reputation, and operational reach—it handles an almost unfathomable volume of American healthcare transactions every day. At about 18 times forward earnings, Humana is marginally richer but still significantly below the overall market. Value-oriented managers typically find it genuinely appealing that both companies trade at less than one times forward sales, a rare feature in today’s market.

UnitedHealth sets itself apart for income-oriented investors with its dividend. In an environment where bonds are fiercely competing for the same capital, a yield that is close to 3% from a company this size and defensive is not insignificant. Humana is a more growth-oriented wager on the earnings recovery story because its dividend profile is less noticeable. Both stocks are currently rated as Hold by Zacks, but ratings typically follow estimates, and the analyst community is openly indicating that EPS revisions upward are likely in the wake of the Medicare Advantage rate decision.

It’s still unclear whether utilization rates will return to normal as many actuaries have hoped or how quickly medical cost trends will stabilize. In a time when healthcare costs are a hot topic in public discourse, both companies are running intricate, politically delicate businesses. Although the CMS tailwind is real, it doesn’t address every cost-related issue. The risk-reward equation has changed; compared to six months ago, when the market was still pricing these stocks for the worst, it now appears significantly better.